Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor
← catalyst calendarSponsored by DexCom, Inc. (industry) · DXCM — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Device feasibility
Enrollment
45actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-11 | actual | When the study began enrolling |
| Primary completion | 2026-01-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes
Interventions
- Drug: Basal insulin — also filed as DexBasal
- Device: Dexcom Continuous Glucose Monitoring (CGM)
Primary outcomes
what the primary-completion date above is the date OFMeasurement of participant safety while using the DexBasal Study System
measured Day 10 up to 8 weeks
Measurement of system recommended dose
measured Day 10 up to 8 weeks
Frequency of Physician approval of Dexbasal Study system's daily dose recommendation
measured Day 10 up to 8 weeks
Subject reported insulin dose
measured Day 10 up to 8 weeks
Evaluation of the CGM Metrics based on average glucose
measured Baseline through end of study, an average of 96 days
Evaluation of the CGM Metrics using coefficient variation (CV)
measured Baseline through end of study, an average of 96 days
Evaluation of the CGM Metrics for time in range (TIR)
measured Baseline through end of study, an average of 96 days
Evaluation of the CGM Metrics of time spent very low
measured Baseline through end of study, an average of 96 days
Evaluation of the CGM Metrics of time spent low
measured Baseline through end of study, an average of 96 days
Evaluation of the CGM Metrics of time spent below 70 mg/dL
measured Baseline through end of study, an average of 96 days
Evaluation of the CGM Metrics of time spent high
measured Baseline through end of study, an average of 96 days
Evaluation of the CGM Metrics of time spent very high
measured Baseline through end of study, an average of 96 days
Measure of glycemic control
measured Baseline through end of study, an average of 96 days
Publications
- PMID 42573729 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · DXCM's whole pipeline · Catalyst calendar · Every registered study · What changed